US20020099075A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
US20020099075A1
US20020099075A1 US10/052,320 US5232002A US2002099075A1 US 20020099075 A1 US20020099075 A1 US 20020099075A1 US 5232002 A US5232002 A US 5232002A US 2002099075 A1 US2002099075 A1 US 2002099075A1
Authority
US
United States
Prior art keywords
carbonyl
guanidine
pyrazole
inhibitor
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/052,320
Other languages
English (en)
Other versions
US6423705B1 (en
Inventor
Wayne Tracey
Roger Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/052,320 priority Critical patent/US6423705B1/en
Application granted granted Critical
Publication of US6423705B1 publication Critical patent/US6423705B1/en
Publication of US20020099075A1 publication Critical patent/US20020099075A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US10/052,320 2001-01-25 2002-01-17 Combination therapy Expired - Fee Related US6423705B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/052,320 US6423705B1 (en) 2001-01-25 2002-01-17 Combination therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26417301P 2001-01-25 2001-01-25
US10/052,320 US6423705B1 (en) 2001-01-25 2002-01-17 Combination therapy

Publications (2)

Publication Number Publication Date
US6423705B1 US6423705B1 (en) 2002-07-23
US20020099075A1 true US20020099075A1 (en) 2002-07-25

Family

ID=26730463

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/052,320 Expired - Fee Related US6423705B1 (en) 2001-01-25 2002-01-17 Combination therapy

Country Status (1)

Country Link
US (1) US6423705B1 (US20020099075A1-20020725-C00010.png)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064854A1 (en) * 2003-01-17 2004-08-05 Korea Institute Of Science And Technology Method for enhancing learning and memory by suppressing the activity of ncx2 protein
US20040198821A1 (en) * 2002-01-29 2004-10-07 Hwang Cheng Shine Reduction of hair growth
WO2005079803A1 (en) * 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
US20060120971A1 (en) * 2004-10-08 2006-06-08 Signum Pharmaceuticals, Inc. Agents and methods for administration to the central nervous system
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
US20070093434A1 (en) * 2003-02-13 2007-04-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20090137665A1 (en) * 2004-03-24 2009-05-28 Mccullough Louise D Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
WO2017007917A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions
CN107661491A (zh) * 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
EP1438085B1 (en) 2001-10-25 2008-10-15 Emory University Catheter for modified perfusion
WO2003061700A1 (fr) * 2002-01-25 2003-07-31 Taisho Pharmaceutical Co.,Ltd. Medicaments servant au traitement de nephropathies chroniques
AU2003211254A1 (en) * 2002-02-15 2003-09-04 Taisho Pharmaceutical Co., Ltd. Remedy for hypertension
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CN100551370C (zh) 2002-05-21 2009-10-21 Cv医药有限公司 雷诺嗪在制备治疗糖尿病的药物组合物中的应用
US6693133B1 (en) * 2002-10-07 2004-02-17 University Of Alberta Methods of cardioprotection using dichloroacetate in combination with an inotrope
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
KR20070046183A (ko) * 2004-09-22 2007-05-02 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는치료 배합물
EP1827298A4 (en) * 2004-12-22 2011-09-28 Univ Emory THERAPEUTIC APPARATUS FOR IMPROVING THE PROTECTIVE EFFECTS OF POST-CONDITIONING ORGANS
US7922669B2 (en) 2005-06-08 2011-04-12 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
US7885710B2 (en) 2005-12-23 2011-02-08 Cardiac Pacemakers, Inc. Method and apparatus for tissue protection against ischemia using remote conditioning
WO2007116243A2 (en) * 2006-04-10 2007-10-18 Mintails Limited Method for treating fibromyalgia and related conditions
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CN101336914B (zh) * 2007-07-03 2011-12-28 常州高新技术产业开发区三维工业技术研究所有限公司 一种缩小心肌梗死面积的药物组合物及其应用
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US20110224606A1 (en) * 2010-03-10 2011-09-15 Shibaji Shome Method and apparatus for remote ischemic conditioning during revascularization
RS56616B1 (sr) 2011-12-31 2018-02-28 Beigene Ltd Kondenzovani tetra ili penta-ciklični dihidrodiazepinokarbazoloni kao parp inhibitori
BR112014016163A8 (pt) 2011-12-31 2017-07-04 Beigene Ltd piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
US9480666B2 (en) 2014-08-16 2016-11-01 Tobias Deuse Compositions and methods for inhibiting intimal hyperplasia
CA3060706A1 (en) * 2017-04-27 2018-11-01 University Of South Alabama Combined administration of cysteine-aspartic protease inhibitors with p2y12 receptor antagonists protects the heart against myocardial infarction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2988487A (en) * 1957-08-29 1961-06-13 Rutgers Res And Educational Fo Process of treating keratinaceous material and a keratinase produced thereby
US3751222A (en) * 1971-12-13 1973-08-07 Colgate Palmolive Co A process of cleaning cloth
US5171682A (en) * 1988-03-31 1992-12-15 North Carolina State University Purified Bacillus licheniformis PWD-1 keratinase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19737224A1 (de) 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
EP1056729B1 (en) 1998-02-27 2004-12-29 Pfizer Products Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2988487A (en) * 1957-08-29 1961-06-13 Rutgers Res And Educational Fo Process of treating keratinaceous material and a keratinase produced thereby
US3751222A (en) * 1971-12-13 1973-08-07 Colgate Palmolive Co A process of cleaning cloth
US5171682A (en) * 1988-03-31 1992-12-15 North Carolina State University Purified Bacillus licheniformis PWD-1 keratinase

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198821A1 (en) * 2002-01-29 2004-10-07 Hwang Cheng Shine Reduction of hair growth
WO2004064854A1 (en) * 2003-01-17 2004-08-05 Korea Institute Of Science And Technology Method for enhancing learning and memory by suppressing the activity of ncx2 protein
US20070093434A1 (en) * 2003-02-13 2007-04-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US7705016B2 (en) 2003-02-13 2010-04-27 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
WO2005079803A1 (en) * 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
US20090137665A1 (en) * 2004-03-24 2009-05-28 Mccullough Louise D Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
US8293791B2 (en) 2004-03-24 2012-10-23 Fasgen, Llc Method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
US20060120971A1 (en) * 2004-10-08 2006-06-08 Signum Pharmaceuticals, Inc. Agents and methods for administration to the central nervous system
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
CN107661491A (zh) * 2010-09-15 2018-02-06 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
WO2017007917A1 (en) * 2015-07-07 2017-01-12 Mast Therapeutics, Inc. Polyoxyethylene/polyoxypropylene copolymers and fibrinolytic inhibitors, uses thereof and compositions

Also Published As

Publication number Publication date
US6423705B1 (en) 2002-07-23

Similar Documents

Publication Publication Date Title
US6423705B1 (en) Combination therapy
US6294538B1 (en) Compounds for treating and preventing diabetic complications
AU733304B2 (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
CA2964760C (en) Composition for prevention or treatment of ischemic cardiac disease,comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient
Bianchi et al. A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs
US20090306160A1 (en) Methods for improving drug disposition
Hock et al. Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion
EP1226830A2 (en) Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia
KR20120078756A (ko) Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한 신규한 신경보호 방법
Munch-Ellingsen et al. 5-HD abolishes ischemic preconditioning independently of monophasic action potential duration in the heart
EA027810B1 (ru) Гетероциклические карбоксамиды для лечения вирусных заболеваний
AU2001288798B2 (en) Use of 20-HETE synthesizing enzyme inhibitors as therapy for cerebral vascular diseases
US5932581A (en) Method of reducing tissue damage associated with ischemia
US5700803A (en) Method for reducing infarct size in subjects afflicted with ischemic heart disease
JP2001500493A (ja) 心臓線維芽細胞の増殖および心線維症を抑制する方法
WO2022141328A1 (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
KR20070006497A (ko) 로지글리타존을 함유하는 패혈성 신장 장해 치료용 약제 조성물
US6852733B2 (en) Sodium-hydrogen exchanger type 1 inhibitor
MXPA00003243A (en) Compounds for treating and preventing diabetic complications

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060723